

AroCell expands cooperation with concile for sales outside of Germany.

AroCell AB and concile GmbH have signed a Letter of Intent to strengthen their partnership and facilitate the sales of their combined product portfolio outside of Germany. Concile, a long-term partner of AroCell, has successfully launched AroCell's product UBC Rapid in the German market. The collaboration will encompass both concile's and AroCell's products in new market launches.

The product portfolio will be based on the same type of readers that AroCell uses today for UBC Rapid. This means that we will be able to offer a combination of tests using the same reader to our end users. We believe that by offering a portfolio of tests centered around UBC Rapid, we significantly increase the attractiveness of our offering to our customers.

AroCell and concile have decided to collaborate to promote and sell their combined product portfolio in markets outside of Germany. This strategic partnership aims to extend their reach and enhance service to customers worldwide. AroCell will be responsible for regulatory approvals and local distributors in the target markets, and also overseeing activities related to the product UBC® Rapid. Concile will, in addition to contributing their product portfolio, provide support in marketing and sales activities outside of Germany.

"The strengthened collaboration with concile allows us to accelerate UBC Rapid's expansion into new markets. Concile's sales expertise combined with their product portfolio will facilitate this process. Together, AroCell and concile form a strong commercial team," says Anders Hultman, CEO of AroCell.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Press Release
08 May 2025 08:30:00 CEST



This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-08 08:30 CEST.

Attachments

[AroCell expands cooperation with concile for sales outside of Germany.](#)